Fig. 4From: Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trialChange in the percentage of patients with no impairment after 48 weeks of treatmentBack to article page